Fw: Attorney Addresses Celebrex Safety Concern & Recommends Reform of the FDA

[Guest guest]

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the

FDA

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the FDA

ATLANTA, Dec. 17 /PRNewswire/ -- Consumer attorney Guerry R. Thornton, Jr., an

Atlanta lawyer who handles Vioxx cases, favors new regulatory reforms in the

wake of news about heart attack risks with Celebrex, Pfizer's blockbuster drug.

" The pace of drug safety issues raises more concern about the effectiveness of

the FDA, " he says. " When drugs show health risks after they are approved,

consumers are correct to ask: Are we being used as guinea pigs to serve the

profit motive of the pharmaceutical industry? "

Thornton will be lobbying Washington for new drug approval laws. He thinks the

system places to much emphasis on perceived benefits and not enough on the

risks. " Like Vioxx, maybe the Celebrex review should have found that heart risks

outweighed its benefits. The FDA relies on drug company data, and this needs to

change, " says Thornton.

The risk of heart attacks has long been a concern related to -2 inhibitors

like Celebrex and Vioxx. " The trial bar acted quickly in the Vioxx controversy

and should use its influence to help bring about reform, " says Thornton.

" Certain senators favor protection for FDA approved drugs. Such laws should not

provide a safe haven for negligent drug companies. "

Today, Pfizer announced findings that indicate a 2.5% increased risk of heart

attacks in Celebrex users. In 2004, 19.8 million prescriptions were filled for

Celebrex. Pfizer's sales have reached over $2 billion per year.

Guerry R. Thornton was involved in the $2.5 billion Dalkon Shield & the $14.5

billion Fen/Phen cases & has written articles for The National Law Journal and

Trial Magazine.

FOR MORE INFORMATION, contact: Guerry Thornton at (404) 933 0298, (404) 467

1670. Visit: http://www.netlaw.net/ for online article about Vioxx and mass tort

cases.

Source: Guerry R. Thornton, Jr.-Netlaw

CONTACT: Guerry Thornton of Netlaw, +1-404-933-0298, or +1-404-467-1670,

or grthorntonjr@...

Web site: http://www.netlaw.net/

--------------------------------------------------------------------------------

Profile: Charly

[Guest guest]

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the

FDA

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the FDA

ATLANTA, Dec. 17 /PRNewswire/ -- Consumer attorney Guerry R. Thornton, Jr., an

Atlanta lawyer who handles Vioxx cases, favors new regulatory reforms in the

wake of news about heart attack risks with Celebrex, Pfizer's blockbuster drug.

" The pace of drug safety issues raises more concern about the effectiveness of

the FDA, " he says. " When drugs show health risks after they are approved,

consumers are correct to ask: Are we being used as guinea pigs to serve the

profit motive of the pharmaceutical industry? "

Thornton will be lobbying Washington for new drug approval laws. He thinks the

system places to much emphasis on perceived benefits and not enough on the

risks. " Like Vioxx, maybe the Celebrex review should have found that heart risks

outweighed its benefits. The FDA relies on drug company data, and this needs to

change, " says Thornton.

The risk of heart attacks has long been a concern related to -2 inhibitors

like Celebrex and Vioxx. " The trial bar acted quickly in the Vioxx controversy

and should use its influence to help bring about reform, " says Thornton.

" Certain senators favor protection for FDA approved drugs. Such laws should not

provide a safe haven for negligent drug companies. "

Today, Pfizer announced findings that indicate a 2.5% increased risk of heart

attacks in Celebrex users. In 2004, 19.8 million prescriptions were filled for

Celebrex. Pfizer's sales have reached over $2 billion per year.

Guerry R. Thornton was involved in the $2.5 billion Dalkon Shield & the $14.5

billion Fen/Phen cases & has written articles for The National Law Journal and

Trial Magazine.

FOR MORE INFORMATION, contact: Guerry Thornton at (404) 933 0298, (404) 467

1670. Visit: http://www.netlaw.net/ for online article about Vioxx and mass tort

cases.

Source: Guerry R. Thornton, Jr.-Netlaw

CONTACT: Guerry Thornton of Netlaw, +1-404-933-0298, or +1-404-467-1670,

or grthorntonjr@...

Web site: http://www.netlaw.net/

--------------------------------------------------------------------------------

Profile: Charly

[Guest guest]

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the

FDA

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the FDA

ATLANTA, Dec. 17 /PRNewswire/ -- Consumer attorney Guerry R. Thornton, Jr., an

Atlanta lawyer who handles Vioxx cases, favors new regulatory reforms in the

wake of news about heart attack risks with Celebrex, Pfizer's blockbuster drug.

" The pace of drug safety issues raises more concern about the effectiveness of

the FDA, " he says. " When drugs show health risks after they are approved,

consumers are correct to ask: Are we being used as guinea pigs to serve the

profit motive of the pharmaceutical industry? "

Thornton will be lobbying Washington for new drug approval laws. He thinks the

system places to much emphasis on perceived benefits and not enough on the

risks. " Like Vioxx, maybe the Celebrex review should have found that heart risks

outweighed its benefits. The FDA relies on drug company data, and this needs to

change, " says Thornton.

The risk of heart attacks has long been a concern related to -2 inhibitors

like Celebrex and Vioxx. " The trial bar acted quickly in the Vioxx controversy

and should use its influence to help bring about reform, " says Thornton.

" Certain senators favor protection for FDA approved drugs. Such laws should not

provide a safe haven for negligent drug companies. "

Today, Pfizer announced findings that indicate a 2.5% increased risk of heart

attacks in Celebrex users. In 2004, 19.8 million prescriptions were filled for

Celebrex. Pfizer's sales have reached over $2 billion per year.

Guerry R. Thornton was involved in the $2.5 billion Dalkon Shield & the $14.5

billion Fen/Phen cases & has written articles for The National Law Journal and

Trial Magazine.

FOR MORE INFORMATION, contact: Guerry Thornton at (404) 933 0298, (404) 467

1670. Visit: http://www.netlaw.net/ for online article about Vioxx and mass tort

cases.

Source: Guerry R. Thornton, Jr.-Netlaw

CONTACT: Guerry Thornton of Netlaw, +1-404-933-0298, or +1-404-467-1670,

or grthorntonjr@...

Web site: http://www.netlaw.net/

--------------------------------------------------------------------------------

Profile: Charly

[Guest guest]

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the

FDA

Attorney Addresses Celebrex Safety Concern & Recommends Reform of the FDA

ATLANTA, Dec. 17 /PRNewswire/ -- Consumer attorney Guerry R. Thornton, Jr., an

Atlanta lawyer who handles Vioxx cases, favors new regulatory reforms in the

wake of news about heart attack risks with Celebrex, Pfizer's blockbuster drug.

" The pace of drug safety issues raises more concern about the effectiveness of

the FDA, " he says. " When drugs show health risks after they are approved,

consumers are correct to ask: Are we being used as guinea pigs to serve the

profit motive of the pharmaceutical industry? "

Thornton will be lobbying Washington for new drug approval laws. He thinks the

system places to much emphasis on perceived benefits and not enough on the

risks. " Like Vioxx, maybe the Celebrex review should have found that heart risks

outweighed its benefits. The FDA relies on drug company data, and this needs to

change, " says Thornton.

The risk of heart attacks has long been a concern related to -2 inhibitors

like Celebrex and Vioxx. " The trial bar acted quickly in the Vioxx controversy

and should use its influence to help bring about reform, " says Thornton.

" Certain senators favor protection for FDA approved drugs. Such laws should not

provide a safe haven for negligent drug companies. "

Today, Pfizer announced findings that indicate a 2.5% increased risk of heart

attacks in Celebrex users. In 2004, 19.8 million prescriptions were filled for

Celebrex. Pfizer's sales have reached over $2 billion per year.

Guerry R. Thornton was involved in the $2.5 billion Dalkon Shield & the $14.5

billion Fen/Phen cases & has written articles for The National Law Journal and

Trial Magazine.

FOR MORE INFORMATION, contact: Guerry Thornton at (404) 933 0298, (404) 467

1670. Visit: http://www.netlaw.net/ for online article about Vioxx and mass tort

cases.

Source: Guerry R. Thornton, Jr.-Netlaw

CONTACT: Guerry Thornton of Netlaw, +1-404-933-0298, or +1-404-467-1670,

or grthorntonjr@...

Web site: http://www.netlaw.net/

--------------------------------------------------------------------------------

Profile: Charly